MONTREAL, QUEBEC–(Marketwired – Jul 7, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries, (“Knight”) announced today that it has expanded its innovative pharmaceutical product sourcing strategy by entering into an agreement with TVM Capital Life Science to invest USD$1.6 million into TVM Life Sciences Venture VII (“TVM Fund”), a fund dedicated to investments in early-stage molecules from pharmaceutical or biotechnology companies as well as technology platforms.
The investment in TVM Fund is the seventh life sciences fund investment Knight Therapeutics Inc. has made to date. The company has now committed over $120 million of the $130 million earmarked for this innovative strategy.
To date, TVM Capital Life Science has EUREUR1.3 billion in assets under management, investing from its seven generations of funds. TVM Capital Life Science has a 30-year track record of identifying promising life sciences products and companies, and supplying them with access to the scientific, capital and management resources critical for success. TVM Fund invests mainly in Canada, the United States, Germany and Western Europe, advised by the TVM Capital Life Science investment teams based in Montreal and Munich.
“Several meaningful opportunities in our deal pipeline have been sourced from our life science fund strategy,” said Jonathan Ross Goodman, Director of Knight. “This strategy will be validated over the next ten years as we launch these life science fund sourced products in Canada and select international markets. We welcome TVM to our family of proven life science funds.”
About TVM Capital Life Science
TVM Capital Life Science is a group of independent investment advisories and fund managers. The teams based in Munich and Montreal advise and manage venture capital funds for investments into innovative biotech, pharmaceutical, and medtech companies in Europe, Canada, U.S. and Asia. For more information, please visit: www.tvm-capital.com or www.tvm-lifescience.com.
About TVM Capital Group
TVM Capital is a group of globally acting venture capital and private equity firms with an operating track record of 30 years. Investment teams have financed more than 250 emerging companies across several industries since 1984. During the last 15 years the firm has become increasingly specialized in the most attractive and high-growth verticals in the broader healthcare markets, with focus areas in financing innovative products and technologies in the European, U.S. and Asian biopharmaceutical and medical device markets, as well as healthcare services in the Middle East and India. For more information, please visit: www.tvm-capital.com.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. The company’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutic Inc.’s Annual Report and in Knight Therapeutic Inc.’s Annual Information Form for the year ended December 31, 2014. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.